Lord, Abbett & Co
HZNP

Lord, Abbett & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Lord, Abbett & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-412,677
Closed -$47M – 654
2022
Q4 		$47M Sell
412,677
-82,452
-17% -$6.85M 0.17% 174
2022
Q3 		$30.6M Sell
495,129
-233,856
-32% -$16.3M 0.11% 246
2022
Q2 		$58.1M Buy
728,985
+253,753
+53% +$24M 0.21% 136
2022
Q1 		$50M Sell
475,232
-41,776
-8% -$4.07M 0.13% 222
2021
Q4 		$55.7M Sell
517,008
-276,307
-35% -$30.1M 0.13% 239
2021
Q3 		$86.9M Buy
793,315
+238,789
+43% +$24.8M 0.21% 155
2021
Q2 		$51.9M Buy
554,526
+147,351
+36% +$13.6M 0.13% 249
2021
Q1 		$37.5M Buy
407,175
+368,698
+958% +$31.1M 0.1% 313
2020
Q4 		$2.81M Buy
38,477
+20,090
+109% +$1.49M 0.01% 616
2020
Q3 		$1.43M Buy
+18,387
New +$1.27M ﹤0.01% 610
2015
Q2 		– Sell
-1,124,104
Closed -$29.2M – 1016
2015
Q1 		$29.2M Buy
+1,124,104
New +$20.6M 0.07% 389

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lord, Abbett & Co's HZNP Position: Q1 2023 in Review

Lord, Abbett & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 412,677 shares — an estimated $47M sold.

Lord, Abbett & Co first reported a position in HZNP in Q1 2015 and held it in 11 quarters. The position peaked at $86.9M in Q3 2021. 552 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Lord, Abbett & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 412,677 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $47M.
  • Lord, Abbett & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 11 quarters.
  • Lord, Abbett & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $86.9M in Q3 2021.
  • 552 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Lord, Abbett & Co's 13F filing for Q1 2023, filed 12 May 2023.